<Suppliers Price>

Suvizumab

Names

[ CAS No. ]:
914257-21-9

[ Name ]:
Suvizumab

Biological Activity

[Description]:

Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab reduces the viral load in HIV-infected patients. Suvizumab has good tolerance in human body and can be used to prevent HIV infection[1][2].

[Related Catalog]:

Signaling Pathways >> Anti-infection >> HIV
Research Areas >> Infection

[Target]

HIV-1

HIV-1 89.6:0.2 μg/mL (IC50)

HIV-1MN:0.1 μg/mL (IC50)

HIV-1SF2:1.0 μg/mL (IC50)


[In Vitro]

Suvizumab 识别 HIV-1 分支 B 分离物中保守的 Pro-Gly-Arg V3 末端序列。Suvizumab 通过匹配的中和序列基序有效中和 CXCR4 和 CCR5 热带原发性 HIV-1 的分支 B 和分支 B’[2]。 Suvizumab 有效中和了 HIV-1MN、HIV-1SF2 和 HIV-189.6，IC50 值分别为 0.1 µg/mL、1.0 µg/mL 和 0.2 µg/mL[2]。 Suvizumab 对 G314E 突变的假型病毒表现出高度抗性[3]。

[In Vivo]

Suvizumab (15、30 和 45 mg/kg；静脉注射；单剂量) 在感染 SHIV C2/1 的食蟹猴中，以剂量依赖性方式弱化了病毒攻击和血浆病毒血症，增加了 CD4+ T 细胞数[2]。 Suvizumab (45 mg/kg；静脉注射；一周一次持续 2 个月) 在感染猿猴/人类免疫缺陷病毒-C2/1 的雄性食蟹猴中，降低了淋巴组织中 CD4 T 细胞的损失[4]。

[References]

[1]. Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS. 2015 Feb 20;29(4):453-62.  

[2]. Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol. 2006 Jun;80(11):5563-70.  

[3]. Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS. 2006 Oct 24;20(16):2065-73.  

[4]. Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS. 2009 Jul 31;23(12):1485-94.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.